1.Investigation and analysis of the current situation of case reporting ethical review and patient informed consent reports in comprehensive journals of clinical medicine in China
Yue CAO ; Yuliang GUI ; Yan YANG ; Le ZHOU ; Wenqi BAO ; Lumin ZHOU ; Qiaoni ZHONG ; Jingyi XIAN ; Di HUANG
Chinese Medical Ethics 2024;37(5):520-525
		                        		
		                        			
		                        			Objective:To investigate and analyze case reporting ethical review and patient informed consent reports published in the comprehensive journals of clinical medicine in China in 2022.Methods:According to the data from the 2022 Edition of the Chinese Science and Technology Journal of the Citation Reports(Extended Version),the case reports published in comprehensive journals of clinical medicine in 2022 were selected as the research objects.The information on ethics and patient informed consent was extracted from the case reports that met the selection criteria,and Microsoft Excel 2021 and SPSS 21.0 were used to sort out and analyze the data.Results:A total of 587 case reporting articles were published in the 42 included journals in 2022,of which 36(6.13%)reported on science and technology ethics and/or informed consent.Case reports reporting on science and technology ethics and/or informed consent mostly came from the key magazine of China technology(88.89%Vs.65.88%),and the proportion of manuscripts involving science and technology ethics on the official website of the journal was relatively high(86.11%Vs.63.88%),and the difference was statistically significant(P<0.01).Conclusion:The proportion of case reports of science and technology ethics and/or informed consent in journals of comprehensive discipline classification of clinical medicine was relatively low.Currently,most international journals are required to obtain the informed consent of patients or legal guardians before publishing case reports.Compared with this,there are still certain gaps in China,which need to be paid great attention to.
		                        		
		                        		
		                        		
		                        	
2.Guidelines for management of pediatric acute hyperextension spinal cord injury.
Lian ZENG ; Yu-Long WANG ; Xian-Tao SHEN ; Zhi-Cheng ZHANG ; Gui-Xiong HUANG ; Jamal ALSHORMAN ; Tracy Boakye SEREBOUR ; Charles H TATOR ; Tian-Sheng SUN ; Ying-Ze ZHANG ; Xiao-Dong GUO
Chinese Journal of Traumatology 2023;26(1):2-7
		                        		
		                        			
		                        			Pediatric acute hyperextension spinal cord injury (SCI) named as PAHSCI by us, is a special type of thoracolumbar SCI without radiographic abnormality and highly related to back-bend in dance training, which has been increasingly reported. At present, it has become the leading cause of SCI in children, and brings a heavy social and economic burden. Both domestic and foreign academic institutions and dance education organizations lack a correct understanding of PAHSCI and relevant standards, specifications or guidelines. In order to provide standardized guidance, the expert team formulated this guideline based on the principles of science and practicability, starting from the diagnosis, differential diagnosis, etiology, admission evaluation, treatment, complications and prevention. This guideline puts forward 23 recommendations for 14 related issues.
		                        		
		                        		
		                        		
		                        			Child
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Spinal Cord Injuries/complications*
		                        			;
		                        		
		                        			Spinal Cord
		                        			
		                        		
		                        	
3.Safety and Comfort Analysis of Distal Transradial Access for Hepatic Artery Infusion Chemotherapy in the Treatment of Liver Cancer
Bin CHEN ; Hai-tao DAI ; Run LIN ; Chun-yong WEN ; Gui-yuan ZHANG ; Xian-hong XIANG ; Jian-yong YANG ; Yong-hui HUANG
Journal of Sun Yat-sen University(Medical Sciences) 2022;43(4):639-644
		                        		
		                        			
		                        			ObjectiveTo evaluate the safety and comfort of hepatic artery infusion chemotherapy (HAIC) via distal transradial access (dTRA) in patients with liver cancer. MethodsPatients with advanced liver cancer who received HAIC via dTRA or transfemoral access (TFA) at the Department of Interventional Radiology, the First Affiliated Hospital of Sun Yat-sen University, were enrolled. The patients underwent dTRA or TFA for onetime and crossed-over subsequently. The patients received HAIC using FOLFOX4 regimen. Postcatheterization questionaire was used to compare the effects of the two vessel accesses on patients’ quality of life. Procedure-related adverse events were also recorded. ResultsAmong the 18 cases enrolled for HAIC, 9 underwent crossover from dTRA to TFA and the the remaining 9 from TFA to dTRA. During HAIC via dTRA, we only found grade 1 or grade 2 procedure-related adverse events such as 2 access site hematoma, 3 persistent pain at access site and 1 left palm numbness. No grade 3 or grade 4 procedure-related adverse event was found. Post dTRA ultrasound revealed no proximal radial artery occlusion. Significant difference in catheterization time between dTRA and TFA accesses was found (4 min vs. 3 min, P < 0.05). All comfort scores were higher with dTRA as compared to TFA and patients preferred dTRA (7.89 vs. 2.72, P < 0.001). The compression time for dTRA access was significantly shorter than TFA access (2 h vs. 7 h, P < 0.05). ConclusionsdTRA approach is safe and tolerable, which is beneficial to improve the quality of life and comfort of patients with liver cancer when undergoing HAIC. 
		                        		
		                        		
		                        		
		                        	
4.Genomic and transcriptomic analysis unveils population evolution and development of pesticide resistance in fall armyworm Spodoptera frugiperda.
Furong GUI ; Tianming LAN ; Yue ZHAO ; Wei GUO ; Yang DONG ; Dongming FANG ; Huan LIU ; Haimeng LI ; Hongli WANG ; Ruoshi HAO ; Xiaofang CHENG ; Yahong LI ; Pengcheng YANG ; Sunil Kumar SAHU ; Yaping CHEN ; Le CHENG ; Shuqi HE ; Ping LIU ; Guangyi FAN ; Haorong LU ; Guohai HU ; Wei DONG ; Bin CHEN ; Yuan JIANG ; Yongwei ZHANG ; Hanhong XU ; Fei LIN ; Bernard SLIPPERS ; Alisa POSTMA ; Matthew JACKSON ; Birhan Addisie ABATE ; Kassahun TESFAYE ; Aschalew Lemma DEMIE ; Meseret Destaw BAYELEYGNE ; Dawit Tesfaye DEGEFU ; Feng CHEN ; Paul K KURIA ; Zachary M KINYUA ; Tong-Xian LIU ; Huanming YANG ; Fangneng HUANG ; Xin LIU ; Jun SHENG ; Le KANG
Protein & Cell 2022;13(7):513-531
		                        		
		                        			
		                        			The fall armyworm (FAW), Spodoptera frugiperda, is a destructive pest native to America and has recently become an invasive insect pest in China. Because of its rapid spread and great risks in China, understanding of FAW genetic background and pesticide resistance is urgent and essential to develop effective management strategies. Here, we assembled a chromosome-level genome of a male FAW (SFynMstLFR) and compared re-sequencing results of the populations from America, Africa, and China. Strain identification of 163 individuals collected from America, Africa and China showed that both C and R strains were found in the American populations, while only C strain was found in the Chinese and African populations. Moreover, population genomics analysis showed that populations from Africa and China have close relationship with significantly genetic differentiation from American populations. Taken together, FAWs invaded into China were most likely originated from Africa. Comparative genomics analysis displayed that the cytochrome p450 gene family is extremely expanded to 425 members in FAW, of which 283 genes are specific to FAW. Treatments of Chinese populations with twenty-three pesticides showed the variant patterns of transcriptome profiles, and several detoxification genes such as AOX, UGT and GST specially responded to the pesticides. These findings will be useful in developing effective strategies for management of FAW in China and other invaded areas.
		                        		
		                        		
		                        		
		                        			Animals
		                        			;
		                        		
		                        			China
		                        			;
		                        		
		                        			Genomics
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Male
		                        			;
		                        		
		                        			Pesticides
		                        			;
		                        		
		                        			Spodoptera/genetics*
		                        			;
		                        		
		                        			Transcriptome
		                        			
		                        		
		                        	
5.Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials.
Hong-Xing PAN ; Jian-Kai LIU ; Bao-Ying HUANG ; Gui-Fan LI ; Xian-Yun CHANG ; Ya-Fei LIU ; Wen-Ling WANG ; Kai CHU ; Jia-Lei HU ; Jing-Xin LI ; Dan-Dan ZHU ; Jing-Liang WU ; Xiao-Yu XU ; Li ZHANG ; Meng WANG ; Wen-Jie TAN ; Wei-Jin HUANG ; Feng-Cai ZHU
Chinese Medical Journal 2021;134(11):1289-1298
		                        		
		                        			BACKGROUND:
		                        			The significant morbidity and mortality resulted from the infection of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) call for urgent development of effective and safe vaccines. We report the immunogenicity and safety of an inactivated SARS-CoV-2 vaccine, KCONVAC, in healthy adults.
		                        		
		                        			METHODS:
		                        			Phase 1 and phase 2 randomized, double-blind, and placebo-controlled trials of KCONVAC were conducted in healthy Chinese adults aged 18 to 59 years. The participants in the phase 1 trial were randomized to receive two doses, one each on Days 0 and 14, of either KCONVAC (5 or 10 μg/dose) or placebo. The participants in the phase 2 trial were randomized to receive either KCONVAC (at 5 or 10 μg/dose) or placebo on Days 0 and 14 (0/14 regimen) or Days 0 and 28 (0/28 regimen). In the phase 1 trial, the primary safety endpoint was the proportion of participants experiencing adverse reactions/events within 28 days following the administration of each dose. In the phase 2 trial, the primary immunogenicity endpoints were neutralization antibody seroconversion and titer and anti-receptor-binding domain immunoglobulin G seroconversion at 28 days after the second dose.
		                        		
		                        			RESULTS:
		                        			In the phase 1 trial, 60 participants were enrolled and received at least one dose of 5-μg vaccine (n = 24), 10-μg vaccine (n = 24), or placebo (n = 12). In the phase 2 trial, 500 participants were enrolled and received at least one dose of 5-μg vaccine (n = 100 for 0/14 or 0/28 regimens), 10-μg vaccine (n = 100 for each regimen), or placebo (n = 50 for each regimen). In the phase 1 trial, 13 (54%), 11 (46%), and seven (7/12) participants reported at least one adverse event (AE) after receiving 5-, 10-μg vaccine, or placebo, respectively. In the phase 2 trial, 16 (16%), 19 (19%), and nine (18%) 0/14-regimen participants reported at least one AE after receiving 5-, 10-μg vaccine, or placebo, respectively. Similar AE incidences were observed in the three 0/28-regimen treatment groups. No AEs with an intensity of grade 3+ were reported, expect for one vaccine-unrelated serious AE (foot fracture) reported in the phase 1 trial. KCONVAC induced significant antibody responses; 0/28 regimen showed a higher immune responses than that did 0/14 regimen after receiving two vaccine doses.
		                        		
		                        			CONCLUSIONS:
		                        			Both doses of KCONVAC are well tolerated and able to induce robust immune responses in healthy adults. These results support testing 5-μg vaccine in the 0/28 regimen in an upcoming phase 3 efficacy trial.
		                        		
		                        			TRIAL REGISTRATION
		                        			http://www.chictr.org.cn/index.aspx (No. ChiCTR2000038804, http://www.chictr.org.cn/showproj.aspx?proj=62350; No. ChiCTR2000039462, http://www.chictr.org.cn/showproj.aspx?proj=63353).
		                        		
		                        		
		                        		
		                        			Adult
		                        			;
		                        		
		                        			COVID-19
		                        			;
		                        		
		                        			COVID-19 Vaccines
		                        			;
		                        		
		                        			Double-Blind Method
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			SARS-CoV-2
		                        			;
		                        		
		                        			Vaccines, Inactivated/adverse effects*
		                        			
		                        		
		                        	
6.Effect of Mmu-circRNA_016901 on the Radiosensitivity of Bone Marrow Mesenchymal Stem Cells.
Jun-Hua ZHANG ; Xian-Hui WEN ; Rong HUANG ; Sai CHEN ; Feng-Xia LIU ; Rong GUI
Journal of Experimental Hematology 2020;28(3):1032-1037
		                        		
		                        			OBJECTIVE:
		                        			To explore the effect of mmu-circRNA_016901 on the regulation of radiation injury of bone marrow stem cells and its mechanism.
		                        		
		                        			METHODS:
		                        			Bone marrow stem cells were exposed to different dose of X-ray, then the expression level of mmu-circRNA_016901 in bone marrow cells treated with different doses of X-ray was detected. The luciferase reporter gene assay was used to confirm that miRNA1249-5p is the target of mmu-circRNA_016901, and RNA Binding Protein Immunoprecipitation was used to confirm that TGF-β3 is the targeted on miRNA1249-5p,the expression of TGF-β3 and cell proliferation were detected after the expression of mmu-circRNA_01690 was regulated.
		                        		
		                        			RESULTS:
		                        			When the irradiation dose<6 Gy, there were significant difference in the expression of mmn-circRNA-016901 after the bone marrow mesenchymal stem cells were treated by different doses of irradiation, which showed a statistically significant (P<0.05). The luciferase reporter gene detection and co-immunoprecipitation experiments confirmed that Mmu-circRNA_016901 could binds to miRNA1249-5p specifically, and overexpression of mmu-circRNA_016901 could regulate miRNA1249-5p negatively, which resulted in a significant increase in TGF-β3 expression and promoting of cell proliferation.
		                        		
		                        			CONCLUSION
		                        			mmu-circRNA_016901 affects the expression of TGF-β3 through miRNA1249-5p, and thus participates in the regulation of the radiation damage mechanism of bone marrow mesenchymal stem cells.
		                        		
		                        		
		                        		
		                        			Bone Marrow Cells
		                        			;
		                        		
		                        			Mesenchymal Stem Cells
		                        			;
		                        		
		                        			RNA, Circular
		                        			;
		                        		
		                        			genetics
		                        			;
		                        		
		                        			Radiation Tolerance
		                        			
		                        		
		                        	
7.Outcomes of 138 myelodysplastic syndrome patients with HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation.
Qian Qian WANG ; Zi Xian LIU ; Xiao Li ZHAO ; Gui Xin ZHANG ; Jian Feng YAO ; Xiao Hui ZHENG ; Li Ning ZHANG ; Yu Yan SHEN ; Xing Li ZHAO ; Yi HE ; Yong HUANG ; Rong Li ZHANG ; Jia Lin WEI ; Qiao Ling MA ; Ai Ming PANG ; Dong Lin YANG ; Wei Hua ZHAI ; Er Lie JIANG ; Si Zhou FENG ; Ming Zhe HAN
Chinese Journal of Hematology 2020;41(2):132-137
		                        		
		                        			
		                        			Objective: To evaluate the outcomes of myelodysplastic syndromes (MDS) patients who received HLA-matched sibling donor allogeneic peripheral blood stem cell transplantation (MSD-PBSCT) . Methods: The clinical data of 138 MDS patients received MSD-PBSCT from Sep. 2005 to Dec. 2017 were retrospectively analyzed, and the overall survival (OS) rate, disease-free survival (DFS) rate, relapse rate (RR) , non-relapse mortality (NRM) rate and the related risk factors were explored. Results: ①After a median follow-up of 1 050 (range 4 to 4 988) days, the 3-year OS and DFS rates were (66.6±4.1) % and (63.3±4.1) %, respectively. The 3-year cumulative incidence of RR and NRM rates were (13.9±0.1) % and (22.2±0.1) %, respectively. ②Univariate analysis showed that patients with grade Ⅲ-Ⅳ acute graft-versus-host disease (aGVHD) or hematopoietic cell transplantation comorbidity index (HCT-CI) ≥2 points or patients in very high-risk group of the Revised International Prognostic Scoring System (IPSS-R) had significantly decreased OS[ (42.9±13.2) %vs (72.9±4.2) %, χ(2)=8.620, P=0.003; (53.3±7.6) %vs (72.6±4.7) %, χ(2)=6.681, P=0.010; (53.8±6.8) %vs (76.6±6.2) %vs (73.3±7.7) %, χ(2)=6.337, P=0.042]. For MDS patients with excess blasts-2 (MDS-EB2) and acute myeloid leukemia patients derived from MDS (MDS-AML) , pre-transplant chemotherapy or hypomethylating agents (HMA) therapy could not improve the OS rate[ (60.4±7.8) %vs (59.2±9.6) %, χ(2)=0.042, P=0.838]. ③Multivariate analysis indicated that the HCT-CI was an independent risk factor for OS and DFS (P=0.012, HR=2.108, 95%CI 1.174-3.785; P=0.008, HR=2.128, 95%CI 1.219-3.712) . Conclusions: HCT-CI was better than the IPSS-R in predicting the outcomes after transplantation. The occurrence of grade Ⅲ-Ⅳ aGVHD is a poor prognostic factor for OS. For patients of MDS-EB2 and MDS-AML, immediate transplantation was recommended instead of receiving pre-transplant chemotherapy or HMA therapy.
		                        		
		                        		
		                        		
		                        			Graft vs Host Disease
		                        			;
		                        		
		                        			Hematopoietic Stem Cell Transplantation
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Leukemia, Myeloid, Acute
		                        			;
		                        		
		                        			Myelodysplastic Syndromes
		                        			;
		                        		
		                        			Retrospective Studies
		                        			;
		                        		
		                        			Siblings
		                        			;
		                        		
		                        			Transplantation Conditioning
		                        			;
		                        		
		                        			Transplantation, Homologous
		                        			
		                        		
		                        	
8.Association of Overlapped and Un-overlapped Comorbidities with COVID-19 Severity and Treatment Outcomes: A Retrospective Cohort Study from Nine Provinces in China.
Yan MA ; Dong Shan ZHU ; Ren Bo CHEN ; Nan Nan SHI ; Si Hong LIU ; Yi Pin FAN ; Gui Hui WU ; Pu Ye YANG ; Jiang Feng BAI ; Hong CHEN ; Li Ying CHEN ; Qiao FENG ; Tuan Mao GUO ; Yong HOU ; Gui Fen HU ; Xiao Mei HU ; Yun Hong HU ; Jin HUANG ; Qiu Hua HUANG ; Shao Zhen HUANG ; Liang JI ; Hai Hao JIN ; Xiao LEI ; Chun Yan LI ; Min Qing LI ; Qun Tang LI ; Xian Yong LI ; Hong De LIU ; Jin Ping LIU ; Zhang LIU ; Yu Ting MA ; Ya MAO ; Liu Fen MO ; Hui NA ; Jing Wei WANG ; Fang Li SONG ; Sheng SUN ; Dong Ting WANG ; Ming Xuan WANG ; Xiao Yan WANG ; Yin Zhen WANG ; Yu Dong WANG ; Wei WU ; Lan Ping WU ; Yan Hua XIAO ; Hai Jun XIE ; Hong Ming XU ; Shou Fang XU ; Rui Xia XUE ; Chun YANG ; Kai Jun YANG ; Sheng Li YUAN ; Gong Qi ZHANG ; Jin Bo ZHANG ; Lin Song ZHANG ; Shu Sen ZHAO ; Wan Ying ZHAO ; Kai ZHENG ; Ying Chun ZHOU ; Jun Teng ZHU ; Tian Qing ZHU ; Hua Min ZHANG ; Yan Ping WANG ; Yong Yan WANG
Biomedical and Environmental Sciences 2020;33(12):893-905
		                        		
		                        			Objective:
		                        			Several COVID-19 patients have overlapping comorbidities. The independent role of each component contributing to the risk of COVID-19 is unknown, and how some non-cardiometabolic comorbidities affect the risk of COVID-19 remains unclear.
		                        		
		                        			Methods:
		                        			A retrospective follow-up design was adopted. A total of 1,160 laboratory-confirmed patients were enrolled from nine provinces in China. Data on comorbidities were obtained from the patients' medical records. Multivariable logistic regression models were used to estimate the odds ratio ( 
		                        		
		                        			Results:
		                        			Overall, 158 (13.6%) patients were diagnosed with severe illness and 32 (2.7%) had unfavorable outcomes. Hypertension (2.87, 1.30-6.32), type 2 diabetes (T2DM) (3.57, 2.32-5.49), cardiovascular disease (CVD) (3.78, 1.81-7.89), fatty liver disease (7.53, 1.96-28.96), hyperlipidemia (2.15, 1.26-3.67), other lung diseases (6.00, 3.01-11.96), and electrolyte imbalance (10.40, 3.00-26.10) were independently linked to increased odds of being severely ill. T2DM (6.07, 2.89-12.75), CVD (8.47, 6.03-11.89), and electrolyte imbalance (19.44, 11.47-32.96) were also strong predictors of unfavorable outcomes. Women with comorbidities were more likely to have severe disease on admission (5.46, 3.25-9.19), while men with comorbidities were more likely to have unfavorable treatment outcomes (6.58, 1.46-29.64) within two weeks.
		                        		
		                        			Conclusion
		                        			Besides hypertension, diabetes, and CVD, fatty liver disease, hyperlipidemia, other lung diseases, and electrolyte imbalance were independent risk factors for COVID-19 severity and poor treatment outcome. Women with comorbidities were more likely to have severe disease, while men with comorbidities were more likely to have unfavorable treatment outcomes.
		                        		
		                        		
		                        		
		                        			Adult
		                        			;
		                        		
		                        			Aged
		                        			;
		                        		
		                        			COVID-19/virology*
		                        			;
		                        		
		                        			China/epidemiology*
		                        			;
		                        		
		                        			Comorbidity
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Male
		                        			;
		                        		
		                        			Middle Aged
		                        			;
		                        		
		                        			Retrospective Studies
		                        			;
		                        		
		                        			Severity of Illness Index
		                        			;
		                        		
		                        			Treatment Outcome
		                        			
		                        		
		                        	
9.PMN-CD11b Levels and Its Correlation with Left Atrial Diameter in Patients with Atrial Fibrillation
Gui-yi YUAN ; Shu-xian ZHOU ; Mei-dan NONG ; Yu-ling ZHANG ; Bo-shui HUANG
Journal of Sun Yat-sen University(Medical Sciences) 2019;40(6):904-911
		                        		
		                        			
		                        			【Objective】To observe the levels of CD11b expressions in the surface of neutrophils in serum,and its correlation with left atrial diameter ,and to study the inflammatory mechanisms in atrial fibrillation(AF) patients. 【Methods】Clinical characteristics and blood samples of AF group and sinal rhythm group were collected. CD11b levels in the surface of neutrophils were examined by flow cytometry. Left atrial diameter was examined by echocardiography. 【Results】The AF group included 85 patients :36 with paroxysmal AF;26 with persistent AF;23 with permanent AF. The sinal rhythm group includes 57 patients. PMN- CD11b levels were significantly higher in Af group than in sinal rhythm group(P<0.01). The left atrial diameter was larger in AF group than in sinal rhythm group(P<0.01). Multivariate analysis revealed that PMN-CD11b,left atrial diameter and Valvular heart disease were independent predictors of atrial fibrillation.【Conclusions】PMN- CD11b levels were elevated in paroxysmal AF when AF was present and in persistent, permanent AF patients,implying atrial fibrillation was closely related to inflammation;PMN-CD11b were correlated with left atrial diameter,inflammation might participate in the atrial structural remodeling in AF patients ;PMN-CD11b levels were elevated in AF patients with high risk thrombosis,inflammation might have some value to embolic risk stratification according to CHA2DS2-VASc score.
		                        		
		                        		
		                        		
		                        	
10.Research on contents of anthraquinones,dianthrones and tannins in Rheum tanguticum on PCA and CA.
Feng HUANG ; Xian-Mei YIN ; Guo-Lin TANG ; Yan LIAN ; Xiao-Fen LIU ; Xin-Mei XU ; Gui-Hua JIANG
China Journal of Chinese Materia Medica 2019;44(5):920-926
		                        		
		                        			
		                        			Anthraquinones,dianthrones and tannins are the main active ingredients of Rheum tanguticum. In this study the three components were determined by HPLC,and the results were analyzed by multiple comparisons,principal components analysis(PCA)and correspondence analysis(CA). The results showed that the contents of components in different growing areas and types(wild and cultivated) reached a significant level(P<0. 05). Baiyu county,Xiaojin county and Ruoergai county had obvious advantages in the accumulation of catechin hydrate,rhien and sensenoside A respectively. The principal component was different in two growing type and the wild environment was conducive to combined anthraquinones accumulation. For active components,normalized planting was better than retail cultivating. Therefore,the effect on the accumulation of chemical components in Rh. tangusticum,should be taken into full account in the selection of the cultural base of Rh. tanguticum. The standardized cultivating is superior to retail cultivating in terms of the accumulation of active ingredients,and standardized planting is inferior to the wild.
		                        		
		                        		
		                        		
		                        			Anthraquinones
		                        			;
		                        		
		                        			analysis
		                        			;
		                        		
		                        			Chromatography, High Pressure Liquid
		                        			;
		                        		
		                        			Drugs, Chinese Herbal
		                        			;
		                        		
		                        			analysis
		                        			;
		                        		
		                        			Phytochemicals
		                        			;
		                        		
		                        			analysis
		                        			;
		                        		
		                        			Plants, Medicinal
		                        			;
		                        		
		                        			chemistry
		                        			;
		                        		
		                        			Rheum
		                        			;
		                        		
		                        			chemistry
		                        			;
		                        		
		                        			Tannins
		                        			;
		                        		
		                        			analysis
		                        			
		                        		
		                        	
            
Result Analysis
Print
Save
E-mail